Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (abre una nueva ventana)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Fuente‎: Hemoglobin 2014;38(1):44-8.

Indexado en‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (abre una nueva ventana)

Hydroxyurea in thalassemia intermedia--a promising therapy. (abre una nueva ventana)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Fuente‎: Ann Hematol 2005;84(7):441-6.

Indexado en‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (abre una nueva ventana)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (abre una nueva ventana)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Fuente‎: J Clin Pathol 2010;63(2):147-50.

Indexado en‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (abre una nueva ventana)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (abre una nueva ventana)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Fuente‎: Eur J Haematol 2009;82(3):213-8.

Indexado en‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (abre una nueva ventana)

Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. (abre una nueva ventana)

Karimi M, Darzi H, Yavarian M.

Fuente‎: J Pediatr Hematol Oncol 2005;27(7):380-5.

Indexado en‎: PubMed 16012328

https://www.ncbi.nlm.nih.gov/pubmed/16012328 (abre una nueva ventana)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (abre una nueva ventana)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Fuente‎: Eur J Haematol 2010;84(1):52-8.

Indexado en‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (abre una nueva ventana)

The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. (abre una nueva ventana)

Koc A, Gumruk F, Gurgey A.

Fuente‎: Pediatr Hematol Oncol 2003;20(6):429-34.

Indexado en‎: PubMed 14631615

https://www.ncbi.nlm.nih.gov/pubmed/14631615 (abre una nueva ventana)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (abre una nueva ventana)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Fuente‎: Ann N Y Acad Sci 2005;1054:250-6.

Indexado en‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (abre una nueva ventana)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (abre una nueva ventana)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Fuente‎: Acta Haematol 2004;111(4):189-95.

Indexado en‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (abre una nueva ventana)

Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients. (abre una nueva ventana)

Elalfy MS, Adly AA, Ismail EA, Elhenawy YI, Elghamry IR.

Fuente‎: Eur J Haematol 2013;91(6):522-33.

Indexado en‎: PubMed 23927461

DOI‎: 10.1111/ejh.12182

https://www.ncbi.nlm.nih.gov/pubmed/23927461 (abre una nueva ventana)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (abre una nueva ventana)

Perrine SP.

Fuente‎: Pediatr Ann 2008;37(5):339-46.

Indexado en‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (abre una nueva ventana)

Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. (abre una nueva ventana)

Rachmilewitz EA, Aker M, Perry D, Dover G.

Fuente‎: Br J Haematol 1995;90(2):341-5.

Indexado en‎: PubMed 7794754

https://www.ncbi.nlm.nih.gov/pubmed/7794754 (abre una nueva ventana)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (abre una nueva ventana)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Fuente‎: Br J Haematol 2011;154(2):281-4.

Indexado en‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (abre una nueva ventana)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (abre una nueva ventana)

Thein SL.

Fuente‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indexado en‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (abre una nueva ventana)

Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of {beta}-thalassemia and sickle-cell anemia. (abre una nueva ventana)

Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R.

Fuente‎: Evid Based Complement Alternat Med 2009;6(2):141-51.

Indexado en‎: PubMed 18955291

DOI‎: 10.1093/ecam/nem139

https://www.ncbi.nlm.nih.gov/pubmed/18955291 (abre una nueva ventana)

A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. (abre una nueva ventana)

Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, Taher A, Chaneim N, Boosalis M, Berenson R, Perrine SP.

Fuente‎: Br J Haematol 2013;161(4):587-93.

Indexado en‎: PubMed 23530969

DOI‎: 10.1111/bjh.12304

https://www.ncbi.nlm.nih.gov/pubmed/23530969 (abre una nueva ventana)

Butyric acid: what is the future for this old substance? (abre una nueva ventana)

Sossai P.

Fuente‎: Swiss Med Wkly 2012;142:w13596.

Indexado en‎: PubMed 22674349

DOI‎: 10.4414/smw.2012.13596

https://www.ncbi.nlm.nih.gov/pubmed/22674349 (abre una nueva ventana)